AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 3117150 — intervention group
Group type: COMPARATOR
Intervention: Control group (normoxic patients)
Number of subjects: 20
Study 28449618 — intervention group
Group type: EXPERIMENTAL
Intervention: Telerehabilitation programme
Number of subjects: 18
Study 28449618 — intervention group
Group type: COMPARATOR
Intervention: Control group (usual face‐to‐face physical therapy)
Number of subjects: 18
Study 27560663 — intervention group
Group type: COMPARATOR
Intervention: Current smokers
Number of subjects: 3043
Study 27560663 — intervention group
Group type: COMPARATOR
Intervention: Secondhand smoke (SHS) exposure at home
Number of subjects: 3043
Study 24506666 — intervention group
Group type: EXPERIMENTAL
Intervention: MAL‐PDT
Number of subjects: 200
Study 24506666 — intervention group
Group type: COMPARATOR
Intervention: DHA
Number of subjects: 200
Study 23510581 — intervention group
Group type: EXPERIMENTAL
Intervention: Intranasal oxytocin (24 IU)
Number of subjects: 14
Study 23510581 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 14
Study 20502134 — intervention group
Group type: EXPERIMENTAL
Intervention: Sublingual tizanidine HCl (8 mg)
Number of subjects: 16
Study 20502134 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral tizanidine HCl (8 mg)
Number of subjects: 16
Study 20502134 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16
Study 20071812 — intervention group
Group type: EXPERIMENTAL
Intervention: Closed reduction and long arm posterior slab application (Group A)
Number of subjects: 60
Study 20071812 — intervention group
Group type: COMPARATOR
Intervention: Closed reduction and percutaneous crossed Kirschner wires fixation (Group B)
Number of subjects: 60
Study 16480168 — intervention group
Group type: EXPERIMENTAL
Intervention: Tiagabine
Number of subjects: 13
Study 16480168 — intervention group
Group type: COMPARATOR
Intervention: Benzodiazepines (oxazepam and lorazepam)
Number of subjects: 13
Study 14530224 — intervention group
Group type: EXPERIMENTAL
Intervention: Rofecoxib, 25 mg/d
Number of subjects: 5557
Study 14530224 — intervention group
Group type: COMPARATOR
Intervention: Naproxen, 500 mg twice daily
Number of subjects: 5557
Study 10346072 — intervention group
Group type: EXPERIMENTAL
Intervention: School-based social competency promotion program
Number of subjects: 0
Study 8965294 — intervention group
Group type: EXPERIMENTAL
Intervention: ISIS group (IG) - received a 30 to 60 min session on the computer in addition to standard cardiovascular education.
Number of subjects: 158
Study 8965294 — intervention group
Group type: COMPARATOR
Intervention: Control group (CG) - received standard cardiovascular education only.
Number of subjects: 158
Study 2000833 — intervention group
Group type: EXPERIMENTAL
Intervention: High-sodium polymeric-glucose solution (maltodextrins 18 g Glucidex 12/L + 2.5 g NaCl/L)
Number of subjects: 6
Study 2000833 — intervention group
Group type: COMPARATOR
Intervention: Standard oral rehydration solution
Number of subjects: 6
Study 6510015 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.05% diflorasone diacetate ointment, once a day
Number of subjects: 70
Study 6510015 — intervention group
Group type: COMPARATOR
Intervention: 0.1% betamethasone valerate ointment, twice a day
Number of subjects: 70
Study 30481110 — intervention group
Group type: EXPERIMENTAL
Intervention: Intramuscular (IM) administration of MMRV vaccine
Number of subjects: 405
Study 30481110 — intervention group
Group type: COMPARATOR
Intervention: Subcutaneous (SC) administration of MMRV vaccine
Number of subjects: 405
Study 29296999 — intervention group
Group type: EXPERIMENTAL
Intervention: 3-D stent retriever with aspiration
Number of subjects: 198
Study 29296999 — intervention group
Group type: COMPARATOR
Intervention: Aspiration alone
Number of subjects: 198
Study 26771705 — intervention group
Group type: EXPERIMENTAL
Intervention: Simulated night work (circadian misalignment)
Number of subjects: 0
Study 26771705 — intervention group
Group type: COMPARATOR
Intervention: Simulated day work (circadian alignment)
Number of subjects: 0
Study 26771705 — intervention group
Group type: EXPERIMENTAL
Intervention: Circadian misalignment
Number of subjects: 0
Study 24347351 — intervention group
Group type: EXPERIMENTAL
Intervention: Glycopyrrolate 0.2 mg
Number of subjects: 66
Study 24347351 — intervention group
Group type: COMPARATOR
Intervention: Normal saline (Control)
Number of subjects: 66
Study 22972032 — intervention group
Group type: EXPERIMENTAL
Intervention: Prednisone 15 mg daily
Number of subjects: 45
Study 22972032 — intervention group
Group type: EXPERIMENTAL
Intervention: Prednisone 7.5 mg daily
Number of subjects: 45
Study 22972032 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 45
Study 20632513 — intervention group
Group type: EXPERIMENTAL
Intervention: Core decompression combined with autologous bone marrow mesenchymal stem cells (BMSCs) transplantation
Number of subjects: 8
Study 20632513 — intervention group
Group type: COMPARATOR
Intervention: Core decompression alone
Number of subjects: 8
Study 18046293 — intervention group
Group type: EXPERIMENTAL
Intervention: Propofol (20 mg bolus and 1.0 mg x kg(‐1) x h(‐1) infusion)
Number of subjects: 90
Study 18046293 — intervention group
Group type: EXPERIMENTAL
Intervention: Midazolam (1 mg bolus and 1.0 mg x h(‐1) infusion)
Number of subjects: 90
Study 18046293 — intervention group
Group type: COMPARATOR
Intervention: Placebo (saline)
Number of subjects: 90
Study 15531670 — intervention group
Group type: EXPERIMENTAL
Intervention: High-intensity exercise (HIE)
Number of subjects: 13
Study 15531670 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-intensity exercise (LIE)
Number of subjects: 13
Study 15531670 — intervention group
Group type: COMPARATOR
Intervention: Control (no exercise)
Number of subjects: 13
Study 11679459 — intervention group
Group type: EXPERIMENTAL
Intervention: Monitoring condition (psychological well-being assessment by diabetes nurse specialist)
Number of subjects: 461
Study 11679459 — intervention group
Group type: COMPARATOR
Intervention: Standard care
Number of subjects: 461
Study 11679459 — intervention group
Group type: EXPERIMENTAL
Intervention: Monitoring condition
Number of subjects: 461
Study 9931805 — intervention group
Group type: COMPARATOR
Intervention: Laparoscopic cholecystectomy without conversion
Number of subjects: 0
Study 9931805 — intervention group
Group type: EXPERIMENTAL
Intervention: Laparotomy conversion
Number of subjects: 0
Study 7825408 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical cyclosporin 2% in olive oil
Number of subjects: 30
Study 7825408 — intervention group
Group type: COMPARATOR
Intervention: Placebo (sterile olive oil)
Number of subjects: 30
Study 2449651 — intervention group
Group type: EXPERIMENTAL
Intervention: Gamma-globulin infusion (GG)
Number of subjects: 29
Study 2449651 — intervention group
Group type: COMPARATOR
Intervention: Aspirin only (Control)
Number of subjects: 29
Study 31036259 — intervention group
Group type: EXPERIMENTAL
Intervention: Reminder + Tetris
Number of subjects: 86
Study 31036259 — intervention group
Group type: EXPERIMENTAL
Intervention: Reminder + Quiz
Number of subjects: 86
Study 31036259 — intervention group
Group type: COMPARATOR
Intervention: Reminder-only
Number of subjects: 86
Study 31036259 — intervention group
Group type: EXPERIMENTAL
Intervention: All groups
Number of subjects: 86
Study 31236580 — intervention group
Group type: EXPERIMENTAL
Intervention: EULAR SS Patients Reported Index (ESSPRI)
Number of subjects: 0
Study 31236580 — intervention group
Group type: EXPERIMENTAL
Intervention: EULAR SS Disease Activity Index (ESSDAI)
Number of subjects: 0
Study 31236580 — intervention group
Group type: EXPERIMENTAL
Intervention: Objective measures for ocular and oral dryness
Number of subjects: 0
Study 31236580 — intervention group
Group type: EXPERIMENTAL
Intervention: New targeted therapies
Number of subjects: 0
Study 28641122 — intervention group
Group type: EXPERIMENTAL
Intervention: 6-session parent-focused intervention (Fear-less Triple P)
Number of subjects: 61
Study 28641122 — intervention group
Group type: COMPARATOR
Intervention: Wait-list control (WL) group
Number of subjects: 61
Study 26475054 — intervention group
Group type: EXPERIMENTAL
Intervention: Albuterol MDPI (180 μg, 2 inhalations of 90 μg each)
Number of subjects: 38
Study 26475054 — intervention group
Group type: COMPARATOR
Intervention: Placebo MDPI
Number of subjects: 38
Study 26475054 — intervention group
Group type: EXPERIMENTAL
Intervention: Albuterol MDPI
Number of subjects: 38
Study 23075427 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise while viewing natural scenes
Number of subjects: 25
Study 23075427 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise while viewing built scenes
Number of subjects: 25
Study 23075427 — intervention group
Group type: COMPARATOR
Intervention: Control group (no specific intervention mentioned)
Number of subjects: 25
Study 21785892 — intervention group
Group type: EXPERIMENTAL
Intervention: Behavioral risks screening (smoking, environmental tobacco smoke exposure, depression, intimate partner violence)
Number of subjects: 1044
Study 21785892 — intervention group
Group type: EXPERIMENTAL
Intervention: CART analysis
Number of subjects: 1044
Study 19103889 — intervention group
Group type: EXPERIMENTAL
Intervention: Gonovaccine provocation
Number of subjects: 204
Study 19103889 — intervention group
Group type: COMPARATOR
Intervention: Control (no provocation)
Number of subjects: 204
Study 16352728 — intervention group
Group type: EXPERIMENTAL
Intervention: Real-time functional MRI (rtfMRI) training
Number of subjects: 0
Study 16352728 — intervention group
Group type: COMPARATOR
Intervention: Sham rtfMRI training
Number of subjects: 0
Study 16352728 — intervention group
Group type: COMPARATOR
Intervention: rtfMRI information from a different brain region
Number of subjects: 0
Study 16352728 — intervention group
Group type: COMPARATOR
Intervention: Training without rtfMRI information
Number of subjects: 0
Study 16352728 — intervention group
Group type: EXPERIMENTAL
Intervention: rtfMRI training in chronic pain patients
Number of subjects: 0
Study 12213081 — intervention group
Group type: EXPERIMENTAL
Intervention: Different types of music
Number of subjects: 60
Study 12213081 — intervention group
Group type: COMPARATOR
Intervention: Silence
Number of subjects: 60
Study 9579447 — intervention group
Group type: EXPERIMENTAL
Intervention: Nonclosure of the peritoneum
Number of subjects: 144
Study 9579447 — intervention group
Group type: COMPARATOR
Intervention: Closed peritoneum (control)
Number of subjects: 144
Study 7898828 — intervention group
Group type: EXPERIMENTAL
Intervention: Esterified estrogens (1.25 mg) and methyltestosterone (2.5 mg) daily for 2 years
Number of subjects: 66
Study 7898828 — intervention group
Group type: COMPARATOR
Intervention: Esterified estrogens (1.25 mg) daily for 2 years
Number of subjects: 66
Study 2523827 — intervention group
Group type: EXPERIMENTAL
Intervention: doxycycline/bensylpenicillin‐procain (DC/BP)
Number of subjects: 64
Study 2523827 — intervention group
Group type: EXPERIMENTAL
Intervention: trimethoprim‐sulfamethoxazole (TMP‐SMZ)
Number of subjects: 64
Study 2523827 — intervention group
Group type: COMPARATOR
Intervention: Not available
Number of subjects: 64
Study 19230 — intervention group
Group type: EXPERIMENTAL
Intervention: Sultopride
Number of subjects: 0
Study 19230 — intervention group
Group type: COMPARATOR
Intervention: Thioproperazine
Number of subjects: 0
Study 31017822 — intervention group
Group type: EXPERIMENTAL
Intervention: ACT017 (doses ranging from 62.5 to 2000 mg)
Number of subjects: 48
Study 31017822 — intervention group
Group type: EXPERIMENTAL
Intervention: ACT017
Number of subjects: 48
Study 31017822 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 48
Study 27557937 — intervention group
Group type: EXPERIMENTAL
Intervention: Ferric pyrophosphate citrate (2.5, 5.0, 7.5, or 10 mg administered over 4 hours; 15 or 20 mg administered over 12 hours)
Number of subjects: 48
Study 27557937 — intervention group
Group type: EXPERIMENTAL
Intervention: Ferric pyrophosphate citrate
Number of subjects: 48
Study 27557937 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 48
Study 26114609 — intervention group
Group type: EXPERIMENTAL
Intervention: Fatigue of the soleus muscle (SOL)
Number of subjects: 11
Study 26114609 — intervention group
Group type: EXPERIMENTAL
Intervention: Fatigue of the gastrocnemius lateralis muscle (GL)
Number of subjects: 11
Study 26114609 — intervention group
Group type: EXPERIMENTAL
Intervention: Fatigue of the gastrocnemius medialis muscle (GM)
Number of subjects: 11
Study 26114609 — intervention group
Group type: EXPERIMENTAL
Intervention: Maximal voluntary torque
Number of subjects: 11
Study 26114609 — intervention group
Group type: EXPERIMENTAL
Intervention: Synergistic voluntary muscle activity
Number of subjects: 11
Study 26114609 — intervention group
Group type: EXPERIMENTAL
Intervention: Spinal reflex activity (H-reflex)
Number of subjects: 11
Study 24118688 — intervention group
Group type: EXPERIMENTAL
Intervention: Canagliflozin 100 mg
Number of subjects: 469
Study 24118688 — intervention group
Group type: EXPERIMENTAL
Intervention: Canagliflozin 300 mg
Number of subjects: 469
Study 24118688 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 469
Study 24118688 — intervention group
Group type: EXPERIMENTAL
Intervention: Canagliflozin 100 mg and 300 mg
Number of subjects: 469
Study 24118688 — intervention group
Group type: EXPERIMENTAL
Intervention: Canagliflozin
Number of subjects: 469
Study 22333443 — intervention group
Group type: EXPERIMENTAL
Intervention: Computer Assisted Minimally Invasive Spine Surgery (CAMISS)
Number of subjects: 97
Study 22333443 — intervention group
Group type: COMPARATOR
Intervention: Traditional Open Surgery (Control)
Number of subjects: 97
Study 19791825 — intervention group
Group type: EXPERIMENTAL
Intervention: Rituximab
Number of subjects: 0
Study 19791825 — intervention group
Group type: EXPERIMENTAL
Intervention: Abatacept
Number of subjects: 0
Study 19791825 — intervention group
Group type: EXPERIMENTAL
Intervention: Tocilizumab
Number of subjects: 0
Study 19791825 — intervention group
Group type: COMPARATOR
Intervention: TNF inhibitors
Number of subjects: 0
Study 19791825 — intervention group
Group type: EXPERIMENTAL
Intervention: All new biological agents
Number of subjects: 0
Study 17092348 — intervention group
Group type: EXPERIMENTAL
Intervention: Diabetes
Number of subjects: 1479
Study 15237126 — intervention group
Group type: EXPERIMENTAL
Intervention: Medial-lateral pin fixation
Number of subjects: 66
Study 15237126 — intervention group
Group type: COMPARATOR
Intervention: 2-lateral pin fixation
Number of subjects: 66
Study 11316024 — intervention group
Group type: EXPERIMENTAL
Intervention: LASIK custom treatment
Number of subjects: 38
Study 11316024 — intervention group
Group type: COMPARATOR
Intervention: LASIK conventional treatment
Number of subjects: 38
Study 11316024 — intervention group
Group type: COMPARATOR
Intervention: Comparative group (one eye custom LASIK and the other eye conventional LASIK)
Number of subjects: 38
Study 9397101 — intervention group
Group type: EXPERIMENTAL
Intervention: Misoprostol tablets (n = 234)
Number of subjects: 467
Study 9397101 — intervention group
Group type: COMPARATOR
Intervention: Misoprostol gel (n = 233)
Number of subjects: 467
Study 8248841 — intervention group
Group type: EXPERIMENTAL
Intervention: Radiation therapy with wedge filter (group B)
Number of subjects: 244
Study 8248841 — intervention group
Group type: COMPARATOR
Intervention: Radiation therapy without wedge filter (group A)
Number of subjects: 244
Study 8248841 — intervention group
Group type: EXPERIMENTAL
Intervention: Radiation therapy with wedge filter for large T1a lesions (group B)
Number of subjects: 244
Study 8248841 — intervention group
Group type: COMPARATOR
Intervention: Radiation therapy without wedge filter for large T1a lesions (group A)
Number of subjects: 244
Study 8248841 — intervention group
Group type: COMPARATOR
Intervention: Minor chronic complications in group A
Number of subjects: 244
Study 8248841 — intervention group
Group type: EXPERIMENTAL
Intervention: Minor chronic complications in group B
Number of subjects: 244
Study 8248841 — intervention group
Group type: EXPERIMENTAL
Intervention: Arytenoid edema in group B
Number of subjects: 244
Study 2884191 — intervention group
Group type: EXPERIMENTAL
Intervention: Penbutolol 40 mg
Number of subjects: 5
Study 2884191 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 5
Study 29901444 — intervention group
Group type: EXPERIMENTAL
Intervention: BioFreedom stent (BFS)
Number of subjects: 104
Study 27576775 — intervention group
Group type: EXPERIMENTAL
Intervention: Ticagrelor 60 mg twice daily
Number of subjects: 14112
Study 27576775 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 14112
Study 27576775 — intervention group
Group type: COMPARATOR
Intervention: More intensive antiplatelet therapy (meta-analysis across 4 trials)
Number of subjects: 14112
Study 25127372 — intervention group
Group type: EXPERIMENTAL
Intervention: Active Online Learning (AOL)
Number of subjects: 214
Study 25127372 — intervention group
Group type: COMPARATOR
Intervention: Passive Online Learning (POL)
Number of subjects: 214
Study 22484638 — intervention group
Group type: EXPERIMENTAL
Intervention: Curcumin (500 mg daily for 7 days)
Number of subjects: 33
Study 22484638 — intervention group
Group type: EXPERIMENTAL
Intervention: Curcumin (50 muM) in vitro
Number of subjects: 33
Study 22484638 — intervention group
Group type: EXPERIMENTAL
Intervention: Curcumin (50 muM) pretreatment
Number of subjects: 33
Study 20845811 — intervention group
Group type: EXPERIMENTAL
Intervention: Panitumumab (single-agent treatment)
Number of subjects: 1
Study 20845811 — intervention group
Group type: COMPARATOR
Intervention: Cetuximab (single-agent treatment)
Number of subjects: 1
Study 18953247 — intervention group
Group type: EXPERIMENTAL
Intervention: Ulinastatin (100,000 U)
Number of subjects: 227
Study 18953247 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 227
Study 15892486 — intervention group
Group type: EXPERIMENTAL
Intervention: Homeopathic treatment (5 globules in a potency of 200c given at 12h interval during ICU stay)
Number of subjects: 70
Study 15892486 — intervention group
Group type: COMPARATOR
Intervention: Placebo (5 globules at 12h interval during ICU stay)
Number of subjects: 70
Study 12151927 — intervention group
Group type: EXPERIMENTAL
Intervention: Epidural blockade with local anesthetic
Number of subjects: 16
Study 12151927 — intervention group
Group type: COMPARATOR
Intervention: Control (general anesthesia alone)
Number of subjects: 16
Study 12151927 — intervention group
Group type: EXPERIMENTAL
Intervention: Both anesthetic techniques
Number of subjects: 16
Study 9915448 — intervention group
Group type: EXPERIMENTAL
Intervention: L-arginine (1,500 mg daily)
Number of subjects: 53
Study 9915448 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 53
Study 7776995 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral anticoagulant therapy with INR between 2.0 and 3.9
Number of subjects: 214
Study 7776995 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral anticoagulant therapy with INR below 2.0
Number of subjects: 214
Study 7776995 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral anticoagulant therapy with INR of 5.0 or above
Number of subjects: 214
Study 7776995 — intervention group
Group type: EXPERIMENTAL
Intervention: Target INR of 3.0
Number of subjects: 214
Study 2333695 — intervention group
Group type: EXPERIMENTAL
Intervention: High dose penicillin
Number of subjects: 88
Study 2333695 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall mortality
Number of subjects: 88
Study 2333695 — intervention group
Group type: EXPERIMENTAL
Intervention: Bilirubin level
Number of subjects: 88
Study 2333695 — intervention group
Group type: EXPERIMENTAL
Intervention: Urine to plasma urea ratio
Number of subjects: 88
Study 2333695 — intervention group
Group type: EXPERIMENTAL
Intervention: Thrombocytopenia
Number of subjects: 88
Study 24061 — intervention group
Group type: EXPERIMENTAL
Intervention: Pipothiazine palmitate
Number of subjects: 32
Study 24061 — intervention group
Group type: COMPARATOR
Intervention: Fluphenazine enanthate
Number of subjects: 32
Study 31955428 — intervention group
Group type: EXPERIMENTAL
Intervention: Artificial Neural Network (ANN) with one hidden layer, 10 nodes, and 10 input features
Number of subjects: 1071
Study 31955428 — intervention group
Group type: EXPERIMENTAL
Intervention: Artificial Neural Network (ANN) trained with IMRT fields
Number of subjects: 1071
Study 31955428 — intervention group
Group type: COMPARATOR
Intervention: Analytic method
Number of subjects: 1071
Study 31496678 — intervention group
Group type: EXPERIMENTAL
Intervention: Tiotropium/olodaterol combination therapy
Number of subjects: 131
Study 31496678 — intervention group
Group type: COMPARATOR
Intervention: Tiotropium monotherapy
Number of subjects: 131
Study 27737566 — intervention group
Group type: EXPERIMENTAL
Intervention: Professional Boundaries for Health Professionals (PBHP) training
Number of subjects: 36
Study 27737566 — intervention group
Group type: COMPARATOR
Intervention: Control group (no training initially)
Number of subjects: 36
Study 27737566 — intervention group
Group type: EXPERIMENTAL
Intervention: Experimental group (PBHP training)
Number of subjects: 36
Study 26363637 — intervention group
Group type: EXPERIMENTAL
Intervention: Azithromycin (30 mg/kg weekly for up to 24 months)
Number of subjects: 391
Study 26363637 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 391
Study 26363637 — intervention group
Group type: EXPERIMENTAL
Intervention: Azithromycin (adherence ≥70%)
Number of subjects: 391
Study 26363637 — intervention group
Group type: EXPERIMENTAL
Intervention: Azithromycin
Number of subjects: 391
Study 23910580 — intervention group
Group type: EXPERIMENTAL
Intervention: Level 1 intervention (information to a pharmacist on facility guideline concordance)
Number of subjects: 220
Study 23910580 — intervention group
Group type: EXPERIMENTAL
Intervention: Level 2 intervention (information to a pharmacist and a list of patients not meeting guideline goals)
Number of subjects: 220
Study 21775554 — intervention group
Group type: EXPERIMENTAL
Intervention: 85% ED (tripled vegetable content)
Number of subjects: 40
Study 21775554 — intervention group
Group type: EXPERIMENTAL
Intervention: 75% ED (quadrupled vegetable content)
Number of subjects: 40
Study 21775554 — intervention group
Group type: COMPARATOR
Intervention: 100% ED (standard condition)
Number of subjects: 40
Study 19846149 — intervention group
Group type: EXPERIMENTAL
Intervention: Doxazosin (0.03 mg/kg daily)
Number of subjects: 39
Study 19846149 — intervention group
Group type: COMPARATOR
Intervention: Ibuprofen (control)
Number of subjects: 39
Study 17110825 — intervention group
Group type: EXPERIMENTAL
Intervention: Methylphenidate (OROS MPH, Concerta) 18‐54 mg/d
Number of subjects: 60
Study 17110825 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study 14740125 — intervention group
Group type: EXPERIMENTAL
Intervention: Adjuvant radiochemotherapy
Number of subjects: 0
Study 14740125 — intervention group
Group type: EXPERIMENTAL
Intervention: Preoperative radiotherapy
Number of subjects: 0